A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma

BACKGROUND: Ipilimumab and peginterferon alfa-2b are established systemic treatment options for melanoma that have distinct mechanisms of action. Given the need for improved therapies for advanced melanoma, we conducted an open-label, single institution, phase Ib study to assess the safety and toler...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:J Immunother Cancer
Hoofdauteurs: Brohl, Andrew S., Khushalani, Nikhil I., Eroglu, Zeynep, Markowitz, Joseph, Thapa, Ram, Chen, Y. Ann, Kudchadkar, Ragini, Weber, Jeffrey S.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: BioMed Central 2016
Onderwerpen:
Research Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5170897/
https://ncbi.nlm.nih.gov/pubmed/28031816
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-016-0194-1
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items